Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Mesoblast (MSB AU): Preparing for Re-Submission of Biologics License Application for Ryoncil

Mesoblast (MSB AU): Trading Halt; Decreased Net Cash Usage in Q4; Positive Clinical Trial Results

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mesoblast-ltd" target="_blank" data-smartkarma-citation="entities:769:1" rel="noopener">Mesoblast Ltd (MSB AU)</a> presented positive results from a phase 3 trial for rexlemestrocel-L, a second-generation cell therapy product candidate derived from its proprietary mesenchymal stromal cell therapy technology platforms.</li>
<li>Rexlemestrocel-L is being studied for advanced chronic heart failure and has the potential to change how currently approve therapies treat heart failure.</li>
<li>Mesoblast expects to receive feedback from the US FDA on potential approval pathways for rexlemestrocel-L by this year. Rexlemestrocel-L has the potential to become a blockbuster drug.</li>
</ul>



Mesoblast Ltd (MSB AU) presented positive results from a phase 3 trial for rexlemestrocel-L, a second-generation cell therapy product candidate derived from its proprietary mesenchymal stromal cell therapy technology platforms.
Rexlemestrocel-L is being studied for advanced chronic heart failure and has the potential to change how currently approve therapies treat heart failure.
Mesoblast expects to receive feedback from the US FDA on potential approval pathways for rexlemestrocel-L by this year. Rexlemestrocel-L has the potential to become a blockbuster drug.


Mesoblast (MSB AU): Gets Closer to FDA Approval Pathways on Positive Phase 3 Clinical Trial Data